Skip to content
MARKETS / NASDAQ / FLNA
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Filana Therapeutics, Inc. FLNA

17 fiscal years on record · USD · FY2025 reported · SEC filings only
$-91.0M
$-32.8M
In brief

What this company does

The company's mission is to develop transformative medicines to improve the lives of patients with central nervous system (CNS) disorders, such as Tuberous Sclerosis Complex (TSC)-related epilepsy and other diseases associated with dysregulation or overexpression of filamin A. The phase out of the company's Alzheimer's disease development program was completed in the second quarter of 2025. The company's lead therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy. On February 26, 2025, the company entered into a License Agreement with Yale University pursuant to which it was granted exclusive worldwide rights, with rights to sublicense, to Yale's interest in certain patent and other intellectual property rights that could be useful or necessary to the development and commercialization of simufilam for the treatment of TSC-related epilepsy and other potential indications. As of December 31, 2025, the company had 17 full-time employees and 3 employees who devote a portion of their professional time to the company, and none of its employees is represented by a labor union or covered under a collective bargaining agreement.

Written from the business description in Filana Therapeutics, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 12 March 2026. Every sentence was checked against that document before publication.

Growth
Revenue, FY2025 · full 17-year series below
Revenue $M Net income $M
FY2013 · Revenue 41.1 · Net income 31.5
20M40M-5M-10M200920112013201520172019202120232025
Compound annual growth
+34.7%
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
Operating margin Net margin
FY2013 · Operating 76.3% · Net 76.7%
20%40%60%-50%200920112013201520172019202120232025
ROE
FY2025 · ROE -82.7%
50%100%-50%200920112013201520172019202120232025

Each USD of equity lost 83 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -32.8
-40M-80M200920112013201520172019202120232025

Total assetsUSD 118.4M
EquityUSD 74.4M
CashUSD 95.5M
Current ratio2.23×

Equity funds 63% of total assets.

The 17-year record
17 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 20252024202320222021202020192018201720162015201420132012201120102009
Revenue $B············0.00.00.00.00.0
Operating income $B−0.1−0.1−0.1−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.00.0−0.0−0.0−0.0−0.0
EBITDA $B−0.1−0.1−0.1−0.1−0.0−0.0−0.0······−0.0−0.0−0.0−0.0
Income tax $B0.00.0··········−0.00.00.0·−0.0
Net income $B−0.1−0.0−0.1−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.00.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.1−0.1−0.1−0.1·−0.0··−0.0−0.0−0.0·····
EPS, diluted $−1.88−1.46−2.32−1.90−0.82−0.24−0.27−0.61−1.82−2.28−0.31−0.270.70−0.08−0.06−0.28−0.08
Dividend / sh $·················
Payout %·················
ROE %−82.7−17.2−53.3−31.7−18.7−11.1−22.2−44.7−84.1−61.9−40.8−28.0102.7−12.0−6.8−17.0−3.2
Shares out B0.050.050.040.040.040.040.020.020.010.010.050.050.050.050.040.04·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 65 reconciliationsAUDITED

Reconciled in 17 of 19 fiscal years. 11 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2009

Share this section

Download image